(Q35116180)

6 August 2017

1 reference

title

Etanercept in psoriatic arthritis. (English)

1 reference

6 August 2017

Allen P Anandarajah

1

1 reference

6 August 2017

Christopher T Ritchlin

series ordinal

2

1 reference

6 August 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

Expert Opinion on Biological Therapy

6 August 2017

published in

1 reference

6 August 2017

volume

3

1 reference

6 August 2017

issue

1

1 reference

6 August 2017

page(s)

169-177

1 reference

Mortality studies in psoriatic arthritis: results from a single outpatient center. II. Prognostic indicators for death.

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

Sulphasalazine in psoriatic arthritis: a double-blind placebo-controlled study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

Cyclosporine for plaque-type psoriasis. Results of a multidose, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

Use of antimalarial drugs for the treatment of psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

Tumour necrosis factor (TNF) in psoriatic arthritis: pathophysiology and treatment with TNF inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

Cytokines in autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

A receptor for tumor necrosis factor defines an unusual family of cellular and viral proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

Macrophage-derived cytokine and nuclear factor kappaB p65 expression in synovial membrane and skin of patients with psoriatic arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

Etanercept in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthropathy: an open pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

Immunomodulatory effects of anti-tumor necrosis factor alpha therapy on synovium in spondylarthropathy: histologic findings in eight patients from an open-label pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (infliximab) versus placebo in active spondylarthropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

Psoriatic arthritis: a quantitative overview of therapeutic options. The Psoriatic Arthritis Meta-Analysis Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

Methotrexate and liver toxicity: role of surveillance liver biopsy. Conflict between guidelines for rheumatologists and dermatologists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.3.1.169

21 January 2018

Identifiers

DOI

10.1517/14712598.3.1.169

1 reference

6 August 2017

1 reference